TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
TAKEDA PHARMACEUTICAL CO LTD
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026
$19.61−0.06 (-0.31%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Takeda Pharmaceutical has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Takeda Pharmaceutical filed with the SEC
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Annual Integrated Report Fiscal year ended March 31, 2026
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Oveporexton Market Opportunity & Commercialization 22
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
2024 Annual Integrated Report Fiscal Year Ended March 31, 2024
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K